141 related articles for article (PubMed ID: 8109893)
1. Amyotrophic lateral sclerosis: theories and therapies.
Rowland LP
Ann Neurol; 1994 Feb; 35(2):129-30. PubMed ID: 8109893
[No Abstract] [Full Text] [Related]
2. New treatment strategies in amyotrophic lateral sclerosis: solutions or illusions?
Robberecht W
Acta Neurol Belg; 1995; 95(2):65-9. PubMed ID: 7618430
[No Abstract] [Full Text] [Related]
3. [Amyotrophic lateral sclerosis].
Moriwaka F
Hokkaido Igaku Zasshi; 1997 Jan; 72(1):21-5. PubMed ID: 9086359
[TBL] [Abstract][Full Text] [Related]
4. [Neurotrophic factors. Therapeutic approach in neurodegenerative diseases].
Wasielewski S
Med Monatsschr Pharm; 1992 Apr; 15(4):98-9. PubMed ID: 1584114
[No Abstract] [Full Text] [Related]
5. Neurotrophic factors in the treatment of motor neuron disease and trauma.
DiStefano PS
Exp Neurol; 1993 Nov; 124(1):56-9. PubMed ID: 8282081
[No Abstract] [Full Text] [Related]
6. Recent advances in the therapy of amyotrophic lateral sclerosis: focus on excitotoxicity.
Brighina L; Sala G; Ceresa C; Tremolizzo L; Ferrarese C
Funct Neurol; 2001; 16(4 Suppl):189-202. PubMed ID: 11996516
[No Abstract] [Full Text] [Related]
7. The use of trophic factors in degenerative motoneuron diseases.
Yan Q; Miller JA
Exp Neurol; 1993 Nov; 124(1):60-3. PubMed ID: 8282082
[No Abstract] [Full Text] [Related]
8. Lay-offs follow suspension of clinical trials of protein.
Verrall M
Nature; 1994 Jul; 370(6484):6. PubMed ID: 8015607
[No Abstract] [Full Text] [Related]
9. [Neurotrophic factor treatment in amyotrophic lateral sclerosis].
Tsuzaka K; Mitsumoto H
No To Shinkei; 1998 Jul; 50(7):625-30. PubMed ID: 9739520
[No Abstract] [Full Text] [Related]
10. New hope for treatment of Lou Gehrig's disease.
Piascik P
J Am Pharm Assoc (Wash); 1996 Jun; NS36(6):355-6. PubMed ID: 8697260
[No Abstract] [Full Text] [Related]
11. Clinical trials in amyotrophic lateral sclerosis: the tenuous past and the promising future.
Choudry RB; Cudkowicz ME
J Clin Pharmacol; 2005 Dec; 45(12):1334-44. PubMed ID: 16291708
[TBL] [Abstract][Full Text] [Related]
12. The design of clinical trials in amyotrophic lateral sclerosis.
Azulay JP
Adv Neurol; 1995; 68():225-7. PubMed ID: 8787233
[No Abstract] [Full Text] [Related]
13. Overview of the pathogenesis and therapy of amyotrophic lateral sclerosis.
Serratrice GT; Munsat TL
Adv Neurol; 1995; 68():1-5. PubMed ID: 8787219
[No Abstract] [Full Text] [Related]
14. "Untreatable" neuromuscular disease. Treatment trials and symptomatic treatment of amyotrophic lateral sclerosis.
Festoff BW; Perurena OH; Singer PA
J Kans Med Soc; 1983 Jun; 84(6):312-7. PubMed ID: 6348186
[No Abstract] [Full Text] [Related]
15. Issues in amyotrophic lateral sclerosis clinical trial design.
Munsat TL
Adv Neurol; 1995; 68():209-18. PubMed ID: 8787231
[No Abstract] [Full Text] [Related]
16. Neurotrophic factors and amyotrophic lateral sclerosis.
Askanas V
Adv Neurol; 1995; 68():241-4. PubMed ID: 8787236
[No Abstract] [Full Text] [Related]
17. Megaslope, natural course, and historical controls in amyotrophic lateral sclerosis trials.
Conradi S; Ronnevi LO
Adv Neurol; 1995; 68():219-24. PubMed ID: 8787232
[No Abstract] [Full Text] [Related]
18. [Interferon in the treatment of amyotrophic lateral sclerosis].
Akimov GA; Golovkin VI; Ankhimova ES; Maiorova LP; Reshetniak AV
Sov Med; 1986; (12):51-5. PubMed ID: 3551109
[No Abstract] [Full Text] [Related]
19. Comment on: "Follow-up study of hyperimmune goat serum (AIMSPRO) for amyotrophic lateral sclerosis".
Day TJ
J Clin Neurosci; 2009 Nov; 16(11):1509-11. PubMed ID: 19695881
[No Abstract] [Full Text] [Related]
20. Guidelines in motor neurone disease (MND)/amyotrophic lateral sclerosis (ALS) - from diagnosis to patient care.
Mitchell JD
J Neurol; 2000 Dec; 247 Suppl 6():VI/7-12. PubMed ID: 19714406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
